Rezolsta is a fixed-dose tablet containing 800mg of darunavir and 150mg of cobicistat.

Darunavir is an HIV protease inhibitor. Cobicistat is used to boost blood levels of darunavir and has no antiviral activity of its own. These drugs reduce the amount of HIV in the body and prevent the development of AIDS-defining illnesses. Rezolsta received marketing approval in the European Union in November 2014. In the United States the fixed-dose tablet was approved with the brand name Prezcobix in January 2015.

Rezolsta is dosed as one pink tablet to be taken once daily with food.

Rezolsta is not suitable for treatment-experienced patients with resistance to darunavir or with viral load above 100,000 copies/ml. Rezolsta is not suitable for people with advanced (decompensated) liver cirrhosis and should be used with caution in people with reduced kidney function (creatinine clearance < 70) when combined with tenofovir, emtricitabine or lamivudine.

The use of cobicistat to boost blood levels of darunavir means that drug interactions with other medications are somewhat different from those reported for darunavir, due to the potential for interactions between both cobicistat and boosted darunavir and other medications.

Rezolsta should not be used in combination with non-nucleoside reverse transcriptase inhibitors (NNRTIs) with the exception of rilpivirine.

The following medicines should not be used in combination with Rezolsta:

  • Carbamazepine, phenobarbital, phenytoin (anticonvulsants)
  • Rifampicin
  • St John's wort
  • Alfuzosin
  • Amiodarone, bepridil, dronedarone, quinidine, ranolazine, systemic lidocaine (antiarrhythmics/antianginals)
  • Astemizole, terfenadine (antihistamines)
  • Colchicine, when used in patients with renal and/or hepatic impairment (antigout)
  • Ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
  • Cisapride
  • Pimozide, quetiapine, sertindole (antipsychotics/neuroleptics)
  • Triazolam, midazolam administered orally
  • Sildenafil and avanafil – when used for the treatment of pulmonary arterial hypertension (PDE-5 inhibitors)
  • Simvastatin and lovastatin
  • Ticagrelor (platelet aggregation inhibitor).

See darunavir for further details of potential side-effects, efficacy and drug resistance.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.